文献速递消化系统肿瘤

尼拉帕利联合纳武利尤单抗或尼拉帕利联合伊匹木单抗治疗铂敏感晚期胰腺癌患者的随机1b/2期试验

Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.
PubMed 文献 · Lancet Oncol · 2022-07-07

这项开放标签随机1b/2期研究将91例铂类治疗后未进展的晚期胰腺癌患者随机分配至尼拉帕利联合纳武利尤单抗组或尼拉帕利联合伊匹木单抗组,主要终点为安全性和6个月无进展生存率。尼拉帕利联合伊匹木单抗组6个月无进展生存率为59.6%,达到主要终点;尼拉帕利联合纳武利尤单抗组为20.6%,劣于无效假设。

要点

  • 尼拉帕利联合伊匹木单抗组6个月无进展生存率为59.6%(95% CI 44.3-74.9;p=0.045),达到主要终点。
  • 尼拉帕利联合纳武利尤单抗组6个月无进展生存率为20.6%(95% CI 8.3-32.9;p=0.0002 vs 无效假设44%)。
  • 尼拉帕利联合伊匹木单抗组3级或以上治疗相关不良事件发生率为50%(23/45),尼拉帕利联合纳武利尤单抗组为22%(10/46)。

核心结论

  • 尼拉帕利联合伊匹木单抗维持治疗组达到6个月无进展生存率主要终点,而尼拉帕利联合纳武利尤单抗组无进展生存劣于无效假设。
  • 这些发现凸显了非细胞毒性维持治疗在晚期胰腺癌患者中的潜力。

研究设计与样本

  • 开放标签、随机、1b/2期研究,纳入至少16周铂类治疗后未进展的晚期胰腺癌患者。
  • 2018年2月7日至2021年10月5日共入组91例患者,随机分配至尼拉帕利联合纳武利尤单抗组(n=46)或尼拉帕利联合伊匹木单抗组(n=45)。
  • 尼拉帕利200 mg口服每日一次;纳武利尤单抗240 mg静脉注射每2周一次(后根据厂家更新改为480 mg静脉注射每4周一次);伊匹木单抗3 mg/kg静脉注射每4周一次共四剂。
  • 主要终点为安全性和6个月无进展生存率;疗效可评估人群84例(尼拉帕利联合纳武利尤单抗组44例,尼拉帕利联合伊匹木单抗组40例)。
  • 中位随访23.0个月(IQR 15.0-31.5)。

主要发现

  • 尼拉帕利联合纳武利尤单抗组6个月无进展生存率为20.6%(95% CI 8.3-32.9;p=0.0002 vs 无效假设44%)。
  • 尼拉帕利联合伊匹木单抗组6个月无进展生存率为59.6%(95% CI 44.3-74.9;p=0.045)。
  • 尼拉帕利联合纳武利尤单抗组10例(22%,10/46)和尼拉帕利联合伊匹木单抗组23例(50%,23/45)发生3级或以上治疗相关不良事件。
  • 尼拉帕利联合纳武利尤单抗组最常见3级或以上不良事件为高血压(4例[8%])、贫血(2例[4%])和血小板减少(2例[4%]);尼拉帕利联合伊匹木单抗组为疲乏(6例[14%])、贫血(5例[11%])和高血压(4例[9%])。
  • 无治疗相关死亡。

关键数值与推荐

  • 6个月无进展生存率无效假设为44%,优效界值为60%,劣效界值为27%。
  • 尼拉帕利联合纳武利尤单抗组6个月无进展生存率20.6%(95% CI 8.3-32.9;p=0.0002 vs 无效假设44%)。
  • 尼拉帕利联合伊匹木单抗组6个月无进展生存率59.6%(95% CI 44.3-74.9;p=0.045)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Establishing alternatives to lifelong chemotherapy for patients with advanced pancreatic cancer has been proposed to address chemotherapy resistance and cumulative toxicity. Poly(ADP-ribose) polymerase (PARP) inhibitors have shown efficacy in this setting, and concurrent immune checkpoint blockade could offer synergistic tumour control. The aim of this study was to test the safety and antitumour activity of maintenance with PARP inhibition combined with immune checkpoint blockade in patients with advanced pancreatic cancer who had a stable response to platinum-based chemotherapy. METHODS: We conducted an open-label, randomised, phase 1b/2 study of niraparib plus anti-PD-1 (nivolumab) or anti-CTLA-4 (ipilimumab) therapy for patients with advanced pancreatic cancer whose cancer had not progressed after at least 16 weeks of platinum-based therapy. Patients were randomly assigned (1:1) via permuted block randomisation (block sizes 2 and 4) to niraparib 200 mg orally per day plus either nivolumab 240 mg intravenously every 2 weeks (later changed to 480 mg intravenously every 4 weeks based on manufacturer update) or ipilimumab 3 mg/kg intravenously every 4 weeks for four doses. The primary endpoints were safety and progression-free survival at 6 months. Treatment groups were not compared for activity, which was assessed in each group against a clinically meaningful progression-free survival at 6 months of 44% (null hypothesis). Superiority of a treatment regimen could be declared if 6-month progression-free survival was 60%, and inferiority if 6-month progression-free survival was 27%. All patients who received at least one dose of study treatment and had at least one post-treatment assessment of response according to Response Evaluation Criteria in Solid Tumours version 1.1 were included in the efficacy population. The safety population consisted of all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT03404960, and enrolment is completed and follow-up is ongoing. FINDINGS: 91 patients were enrolled between Feb 7, 2018, and Oct 5, 2021 and were randomly assigned to niraparib plus nivolumab (n=46) or niraparib plus ipilimumab (n=45). Of these patients, 84 were evaluable for the progression-free survival endpoint (niraparib plus nivolumab=44; niraparib plus ipilimumab=40). Median follow-up was 23·0 months (IQR 15·0-31·5). 6-month progression-free survival was 20·6% (95% CI 8·3-32·9; p=0·0002 vs the null hypothesis of 44%) in the niraparib plus nivolumab group; and 59·6% (44·3-74·9; p=0·045) in the niraparib plus ipilimumab group. Ten (22%) of 46 patients in the niraparib plus nivolumab group and 23 (50%) of 45 patients in the niraparib plus ipilimumab group had a grade 3 or worse treatment-related adverse event. The most common grade 3 or worse adverse events in the niraparib plus nivolumab group were hypertension (in four [8%] patients), anaemia (two [4%]), and thrombocytopenia (two [4%]) whereas in the niraparib plus ipilimumab group these were fatigue (in six [14%]), anaemia (five [11%]), and hypertension (four [9%]). There were no treatment-related deaths. INTERPRETATION: The primary endpoint of 6-month progression-free survival was met in the niraparib plus ipilimumab maintenance group, whereas niraparib plus nivolumab yielded inferior progression-free survival. These findings highlight the potential for non-cytotoxic maintenance therapies in patients with advanced pancreatic cancer. FUNDING: Bristol Myers Squibb, GlaxoSmithKline, the Basser Center Young Leadership Council, The Konner Foundation, The Pearl and Philip Basser Innovation Research Award, the Anonymous Foundation, and the US National Institutes of Health.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Reiss KA, Mick R, Teitelbaum U, et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. Lancet Oncol. 2022. PMID: 35810751. doi:10.1016/S1470-2045(22)00369-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。